摘要:
Novel 1,4,8-triazaspiro[4,5]decan-2-one compounds corresponding to formula I processes for the preparation thereof, related methods of treatment and pharmaceutical formulations containing such compounds.
摘要:
Saturated and unsaturated heteroarylcycloalkylmethyl-amine compounds corresponding to formula I, processes for their preparation, pharmaceutical formulations comprising these compounds and the use of saturated and unsaturated heteroarylcycloalkylmethyl-amines for the preparation of pharmaceutical formulations. pharmaceutical formulations and related methods of treatment or prophylaxis of certain condition, especially depression and/or pain, are also disclosed.
摘要:
Spirocyclic cyclohexane compounds corresponding to formula I a process for manufacturing such compounds, pharmaceutical compositions that contain such compounds, and the use of such spirocyclic cyclohexane compounds for the production of pharmaceuticals, and particularly for the treatment of pain.
摘要:
Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.
摘要翻译:对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。
摘要:
Substituted imidazoline derivatives corresponding to Formula I: a method for producing them from substituted aldehyde compounds of Formula B: and the use of such imidazoline derivatives and aldehyde compounds to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug misuse, drug dependency, lethargy and/or anxiety.
摘要:
Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.
摘要翻译:对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。
摘要:
The invention relates to the use of substituted 4-amino-1-phenylbutan-2-ol compounds in the form of their racemates, enantiomers, diastereomers or corresponding bases or corresponding salts of physiologically acceptable acids as regulators for the nociceptin/orphanin-FQ ligand ORL1 receptor system and for the production of medicaments.
摘要:
Substituted imidazo[1,2-a]pyridine compounds, a process for the production thereof, pharmaceutical preparations containing such compounds and methods of using such substituted imidazo[1,2-a]pyridine compounds to treat and/or inhibit various diseases or pathological conditions.
摘要:
Substituted 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl and 5,6,7,8-tetrahydro-quinazolin-2-yl compounds, corresponding to formula I processes for the production thereof, pharmaceutical preparations containing these compounds the use thereof for the production of pharmaceutical preparations and related method of treating or inhibiting certain disorders or conditions, including pain.
摘要:
Substituted 2-pyrrolidin-2-yl compounds corresponding to formula I a method for their production, pharmaceutical compositions containing them, and methods of using them, especially for treating pain and/or depression.